KCT0009077
Not yet recruiting
未知
Diabetes-Centered Evaluation of Revascularization Strategy of Functional and Imaging-CombiNEd State-of-the-Art Percutaneous Coronary Intervention or Coronary-Artery Bypass Grafting in Patients with Diabetes Mellitus and Multivessel Coronary Artery Disease
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Asan Medical Center
- Enrollment
- 1360
- Status
- Not yet recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Inclusion Criteria: subject must have met all of the following criteria to be eligible for treatment in the study:
- •1\.The subject must be \=20 years of age with angina and/or evidence of myocardial ischemia
- •2\.Patients with type 2 diabetes based on the need for treatment with insulin or oral hypoglycemic drugs or a confirmed elevated blood glucose level (fasting plasma glucose elevation on \>1 occasion of \=126 mg/dL \[7\.0 mmol/L] or 2\-h postprandial of \=200 mg/dL \[11\.1 mmol/L] during oral glucose tolerance test or random plasma glucose of \=200 mg/dL \[11\.1 mmol/L] with classic symptoms of hyperglycemia or hyperglycemic crisis or HbA1C \=6\.5% \[48 mmol/mol]) (17\).
- •3\.Significant multivessel CAD (defined as \= 50% diameter stenosis \[DS] by visual estimation) of major epicardial vessels with LAD involvement and amenable to revascularization (equally suitable) by both PCI and CABG as determined by the Heart Team.
- •4\.The patient or guardian agrees to the study protocol and the schedule of clinical follow\-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board or Ethical Committee of the respective clinical site.
Exclusion Criteria
- •Exclusion Criteria: Subjects were to be excluded from the study if any of the following criteria were met:
- •1\.Unprotected left main coronary artery disease requiring revascularization
- •2\.The presence of complex CAD anatomy or lesion characteristics or other cardiac condition(s) which leads the participating interventional cardiologist to believe that PCI is not suitable (i.e., the subject should be managed with CABG or medical therapy alone)
- •3\. Recent STEMI (\<5 days prior to randomization)
- •4\.Cardiogenic shock and/or need for mechanical/pharmacologic hemodynamic support
- •5\.Severe left ventricular dysfunction (ejection fraction \<30%)
- •6\. Requirement for other cardiac or non\-cardiac surgical procedure (e.g., valve replacement, aorta surgery, or carotid revascularization). However, a maze procedure or pulmonary vein isolation is allowed
- •7\.Contraindication or inability to take aspirin or P2Y12 inhibitors (clopidogrel, ticagrelor, or clopidogrel) for at least 6 months
- •8\.Prior CABG
- •9\.Extremely calcified or tortuous vessels precluding FFR measurement or intracoronary imaging evaluation
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 4
Multiclinical Study for Diabetic Macrovascular complications(MSDM)JPRN-UMIN000006244MSDM900
Completed
Not Applicable
Clinical benefit for diabetic vascular complication on non-invasive measurement of advanced glycogen endproduct level in type 2 diabetesJPRN-UMIN000024756Human Ethics Review Committee of Kumamoto University600
Not yet recruiting
Not Applicable
Diabetes REarCh on patient sTratification (DIRECT) work package 3.2: metformin intoleranceType 2 Diabetes Mellitus1001842410012653NL-OMON38746Vrije Universiteit Medisch Centrum150
Not yet recruiting
Not Applicable
Study on complications of diabetes and risk of heart attackCTRI/2019/01/017120Osmania Medical College
Unknown
Not Applicable
Reversal of diabetes and prevention of arteriosclerosis in type 2 diabetic patients with oral antidiabetic agentsType2 Diabetes MellitusJPRN-UMIN000000947PREVENT-J Study Steering Committee500